Thomas Powles

TL;DR: Patients and clinicians should consider the oncologic risk of delayed cancer intervention versus the risks of COVID-19 to the patient, treating health care professionals, and the health care system.

TL;DR: A systematic review and meta-analysis of relevant literature comparing the oncological outcomes and adverse events of different systemic therapies for patients with metastatic non-ccRCC suggested that a drug called sunitinib might be more effective than everolimus, but the statistics supporting this statement are not yet entirely reliable.

TL;DR: There was an overall increase in the percentage of patients presenting with stage I seminoma, with a significant reduction in the size of the primary tumour.

TL;DR: Upfront sunitinib prior to planned nephrectomy in intermediate-risk disease is associated with a median survival of >2 yr despite frequent progression during treatment break, and progression in metastatic sites prior toplanned surgery and MSKCC poor- risk disease was associated withA poor outcome.

TL;DR: MPDL3280A, a human monoclonal antibody containing an engineered Fc-domain designed to optimize efficacy and safety, targets PD-L1, blocking PD- L1 from binding its receptors, including PD-1 and B7, in human RCC.